🇺🇸 FDA
Patent

US 10654829

Crystalline forms and compositions of CFTR modulators

granted A61KA61K9/10A61K9/2013

Quick answer

US patent 10654829 (Crystalline forms and compositions of CFTR modulators) held by Vertex Pharmaceuticals Incorporated expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K9/10, A61K9/2013, A61K9/2054, A61P